ORMALVI (Dichlorphenamide) Tablets

Helping to take care of your patients with Primary Periodic Paralysis.

ORMAVLI is for patients with Primary Periodic Paralysis, including hyperkalemic periodic paralysis, hypokalemic periodic paralysis and related variants.1

It can help your patients feel more confident by reducing the frequency and severity of attacks.2

Find out moreEnroll your patients now
Man taking a death breath

NOT ACTUAL PATIENT

Product

Dichlorphenamide is the only medication approved by the FDA for the treatment of Primary Periodic Paralysis and it is well tolerated in patients with Primary Periodic Paralysis.3

ORMALVI is:

Check Icon

Available in 50 mg tablets.2

Check Icon

A proven treatment for Primary Periodic Paralysis.3

Check Icon

The same proven dichlorphenamide your patients are familiar with.2

Find out more

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita™, our dedicated hub support program, which delivers individualized product support* at every step. Including:

Check Icon

Bridge Program*

Check Icon

Co-pay Assistance Program*

Check Icon

Continuous Clinical Product Support

Check Icon

Patient Nutrition Program*

Find out more

What is Primary Periodic Paralysis?

Primary Periodic Paralysis is a rare autosomal-dominant disease characterized by severe episodes of muscle weakness concomitant to variations in blood potassium levels.

Find out more about Primary Periodic Paralysis on our website, including what causes it and how to diagnose it. You can also hear from an expert about symptoms, patient examples and diagnosis across our video series.

Find out more about Primary Periodic Paralysis

References

  1. ORMALVI (dichlorphenamide). Prescribing Information. Cycle Pharmaceuticals Ltd.
  2. Statland, J., et al (2017). Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle & Nerve, [online] 57(4), pp.522–530. Available at:: https://doi.org/10.1002/mus.26009 [Accessed 1 Nov. 2023].
  3. Greig. S. L., (2016). Drugs. Dichlorphenamide: A Review in Primary Periodic Paralyses. 76 (4): 501-507. Available at: https://doi.org/10.1007/s40265-016-0559-2 [Accessed 1 Nov. 2023].

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.